Contact | Print version | PDF version | Send article | RSS feed

TranScrip Partners appoints David Oxlade as Chairman of the Board

05 Nov 2009 - TranScrip Partners LLP, a pharmaceutical development company providing expert advice and hands-on support to pharmaceutical and biotechnology companies across a wide range of therapeutic areas, announced the appointment of David Oxlade to the position of Chairman of the Board.
 
David Oxlade is a former CEO of Xenova, the LSE and NASDAQ listed biotechnology company, and in 2006 was appointed Chairman of BioAnaLab, the analytical service organisation acquired in 2009 by Millipore Corporation. Prior to their acquisition by Roche, David spent 14 years working for Boehringer Mannheim and a further seven serving as President of Californian-based, Syva (a subsidiary of Hoechst AG),.
 
David is an Honorary Fellow of Brunel University, has held membership of the Emerging Enterprise Council of EuropaBio and the Bioscience Leadership Council since its inception. He has chaired the European Working Group of the Bioscience Innovation and Growth Team, set up by the UK Government under Sir David Cooksey to establish a ten year agenda for its bioscience industry.